Lp(a) Isn’t Just Another Lipid It’s a Distinct Cardiovascular Risk Pathway
For decades, cardiovascular risk assessment has been dominated by traditional lipid markers — particularly LDL cholesterol.
And for good reason. LDL is well understood, measurable, and, importantly, modifiable.
But a growing body of evidence is pointing to something else:
A risk factor that behaves differently.
A risk factor that operates independently.
And one that is still not routinely identified in clinical practice.
That risk factor is Lipoprotein(a), or Lp(a).
A clearer picture is emerging
A recent large-scale study, analysing data from over 425,000 participants in the UK Biobank, adds significant weight to what many clinicians have suspected for some time.
The findings are striking.
Lp(a) was shown to have a direct, causal effect on coronary artery disease — and crucially, this effect is independent of LDL cholesterol.
This is an important distinction.
Because it means that even when LDL is well controlled — whether through lifestyle or pharmacological intervention — Lp(a) may still be driving cardiovascular risk.
Not just another marker
What makes this study particularly interesting is not just the strength of the association, but its specificity.
Out of more than 1,400 phenotypes analysed, Lp(a) demonstrated a direct causal relationship with:
- Coronary artery disease
- And, to a lesser extent, HbA1c
That’s it.
Not across a broad range of metabolic or systemic conditions — but a targeted, specific effect on cardiovascular disease.
This reinforces the idea that Lp(a) is not simply another component of the lipid profile.
It represents a distinct biological pathway contributing to atherosclerosis.
Rethinking thresholds and risk
The study also raises questions about how we define “high” Lp(a).
Current guideline thresholds are typically set around 125 nmol/L. However, this analysis suggests that cardiovascular risk may begin to increase at lower levels.
If that’s the case, it has implications for how we:
- Identify at-risk patients
- Stratify populations
- And intervene earlier in the disease pathway
What about diabetes risk?
One concern that has been raised historically is whether very low Lp(a) levels might be associated with an increased risk of diabetes.
This study provides some reassurance.
There was no clear causal link between low Lp(a) and type 2 diabetes, suggesting that reducing Lp(a) — as emerging therapies aim to do — is unlikely to introduce unintended metabolic risk.
The bigger question: are we identifying it?
All of this leads to a more practical question.
If Lp(a) is:
- Causal
- Independent
- And relatively common
Why isn’t it routinely measured?
In many pathways today, it still isn’t.
Which means that a proportion of patients — including those with well-controlled LDL — may have residual, unrecognised cardiovascular risk.
From evidence to implementation
We’ve become increasingly sophisticated in how we understand cardiovascular disease.
We can model risk, stratify populations, and personalise treatment.
But that sophistication only has value if the right markers are being measured in the first place.
Lp(a) challenges us to rethink a familiar model.
Not to replace what already works — but to recognise that traditional lipid testing may not tell the full story.
Where this creates an opportunity
As focus shifts toward earlier identification of cardiovascular risk, there is growing interest in how testing can be made more accessible and actionable within routine care.
In particular, approaches that bring advanced lipid testing closer to the point of care — enabling results to be available during the same consultation — have the potential to:
- Support more personalised risk discussions
- Improve patient engagement
- Reduce delays between testing and decision-making
At Connect2Pharma, this is an area we are actively exploring through point-of-care and near-patient diagnostic solutions, including technologies that enable rapid measurement of markers such as ApoB and Lp(a).
Cardiovascular prevention has always been about identifying risk early enough to change outcomes.
Lp(a) doesn’t just add another data point.
It highlights a gap.
And increasingly, it’s a gap we now have both the evidence — and the tools — to address.